The significance of scirrhous gastric cancer cell lines: the molecular characterization using cell lines and mouse models

Hum Cell. 2018 Oct;31(4):271-281. doi: 10.1007/s13577-018-0211-4. Epub 2018 Jun 6.

Abstract

Scirrhous gastric cancer (SGC) exhibits aggressiveness of the rapid infiltrating tumor cells with abundant fibroblasts. Experimental studies using SGC cell lines have obtained useful information about this cancer. Our literature search divulged a total of 18 SGC cell lines; two cell lines were established from primary SGC and the other lines were established from a metastatic lesion of SGC. Fibroblast growth factor receptor 2 (FGFR2) and transforming growth factor-beta receptor (TβR) are linked to the rapid development of SGC. Cross-talk between the cancer cells and cancer-associated fibroblasts (CAFs) has been shown to contribute to the progression of SGC. Chemokine (C-X-C motif) receptor 1 (CXCR1) from SGC cells might be associated with the abundant CAFs in cancer microenvironments. The in vivo models established using SGC cell lines are expected to serve as a useful tool for the development of drugs such as FGFR2 inhibitors, TβR inhibitors, and CXCR1 inhibitors, which might be promising as SGC treatments. However, the number of available SGC cell lines is insufficient for the clarification of the entire biologic behavior of SGC. Since the mechanisms responsible for the characteristic aggressiveness of SGC are not fully elucidated, the establishment of new SGC cell lines could help clarify the biological behavior of SGC and contribute to its treatment.

Keywords: Cell line; Characterization; Establishment; Mouse models; Scirrhous gastric cancer.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma, Scirrhous / genetics*
  • Adenocarcinoma, Scirrhous / pathology*
  • Adenocarcinoma, Scirrhous / therapy
  • Adult
  • Aged
  • Animals
  • Cancer-Associated Fibroblasts
  • Cell Line, Tumor
  • Disease Models, Animal
  • Disease Progression
  • Female
  • Humans
  • Male
  • Mice
  • Middle Aged
  • Molecular Targeted Therapy
  • Receptor, Fibroblast Growth Factor, Type 2
  • Receptors, Interleukin-8A
  • Receptors, Transforming Growth Factor beta
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / pathology*
  • Tumor Microenvironment / genetics

Substances

  • Receptors, Interleukin-8A
  • Receptors, Transforming Growth Factor beta
  • Receptor, Fibroblast Growth Factor, Type 2